&Partners’s Novo Nordisk NVO Stock Holding History

&Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.39M	Buy	117,724 +31,552	+37%	+$1.5M	0.02%	567
2025 Q4	$4.47M	Buy	86,172 +20,200	+31%	+$1.03M	0.02%	536
2025 Q3	$3.66M	Sell	65,972 -34,558	-34%	-$2.02M	0.02%	521
2025 Q2	$6.92M	Sell	100,530 -31,147	-24%	-$2.12M	0.05%	305
2025 Q1	$9.12M	Buy	131,677 +3,332	+3%	+$275K	0.1%	201
2024 Q4	$11.3M	Buy	128,345 +80,819	+170%	+$8.74M	0.14%	151
2024 Q3	$5.64M	Buy	47,526 +31,931	+205%	+$4.26M	0.11%	187
2024 Q2	$2.23M	Buy	15,595 +9,495	+156%	+$1.26M	0.1%	198
2024 Q1	$783K	Buy	+6,100	New	+$726K	0.11%	191

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

&Partners's NVO Position: Q1 2026 in Review

&Partners increased its Novo Nordisk (NVO) stake by 37% in Q1 2026, buying an estimated $1.5M and bringing the position to 117,724 shares worth $4.39M. The position accounts for 0.02% of the portfolio, ranked #567.

&Partners first reported a position in NVO in Q1 2024 and has held it in 9 quarters since. The position peaked at $11.3M in Q4 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

&Partners held 117,724 shares of Novo Nordisk worth $4.39M as of Q1 2026.
&Partners bought 31,552 Novo Nordisk shares in Q1 2026, an estimated $1.5M.
Novo Nordisk made up 0.02% of &Partners's portfolio in Q1 2026, its #567 holding.
&Partners first reported a position in Novo Nordisk in Q1 2024 and has held it in 9 quarters since.
&Partners's Novo Nordisk position peaked at $11.3M in Q4 2024.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.